【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
2.12 Currency Exchange Rates in This Report
3. Ophthalmic Drugs: World Market 2015-2025
3.1 The World Ophthalmic Drugs Market in 2014
3.2 World Ophthalmic Drugs Market: Sales Forecast 2015-2025
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2015-2025
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2015-2025
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2015-2025
3.5.3 Glaucoma Drugs Market: Sales Forecast 2015-2025
3.5.4 Dry Eye Drugs Market: Sales Forecast 2015-2025
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2015-2025
3.6 How Will Segmental Market Shares Change to 2025?
3.7 CAGR Forecasts of Ophthalmic Drugs Markets From 2014-2025
3.8 Market Attractiveness of Ophthalmic Drugs Markets in 2019
3.9 Market Attractiveness of Ophthalmic Drugs Markets in 2025
3.10 World Ophthalmic Drugs Market: Drivers and Restraints 2015-2025
3.10.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.10.2 World Ophthalmic Drugs Market: Analysis of Restraints
4. Leading US Ophthalmic Drug Manufacturers 2015-2025
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Generic Launch in 2015?
4.1.1.2 Restasis: Sales Forecast 2015-2025
4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
4.1.1.4 Lumigan and Ganfort: Sales Forecast 2015-2025
4.1.1.5 Refresh Brand Products: the Range
4.1.1.6 Refresh Brand Products: Sales Forecast 2015-2025
4.1.1.7 Alphagan/Alphagan P and Combigan: Extended Lifecycle
4.1.1.8 Alphagan/Alphagan P and Combigan: Sales Forecast 2015-2025
4.1.1.9 Acular: New Forms Receiving FDA Approvals
4.1.1.10 Acular: Sales Forecast 2015-2025
4.1.1.11 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
4.1.2 Allergan: Ophthalmic Product Pipeline
4.1.2.1 Novadur (Intravitreal Brimonidine Implant)
4.1.2.2 AGN 208397 (Beclomethasone Intravitreal Injection)
4.1.2.3 Anti-VEGF DARPins (VEGF Inhibitors)
4.1.3 Allergan: Ophthalmic Revenue Forecast 2015-2025
4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2015-2025
4.1.4 Allergan: SWOT Analysis
4.2 Merck Overview
4.2.1 Merck: Exiting the Ophthalmic Drugs Market
4.2.2 Merck: Ophthalmic Product Pipeline
4.2.3 Merck: Ophthalmic Drugs Sales in 2013 and 2014
4.3 Pfizer Overview
4.3.1 Pfizer: Ophthalmic Product Portfolio
4.3.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
4.3.1.2 Xalatan/Xalacom: Sales Forecast 2015-2025
4.3.2 Pfizer: Ophthalmic Product Pipeline
4.3.3 Pfizer: Revenue Forecast 2015-2025
4.3.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2015-2025
4.3.4 Pfizer: SWOT Analysis
4.4 Regeneron Overview
4.4.1 Regeneron: Ophthalmic Product Portfolio
4.4.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.4.1.2 Eylea: US Sales Forecast 2015-2025
4.4.2 Regeneron: Ophthalmic Product Pipeline
4.4.3 Regeneron: Revenue Forecast 2015-2025
4.4.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2015-2025
4.4.4 FDA Approves Zaltrap (aflibercept)
4.4.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.4.6 Regeneron: SWOT Analysis
4.5 Akorn Overview
4.5.1 Akorn: Ophthalmic Product Portfolio
4.5.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
4.5.1.2 AzaSite: Sales Forecast 2015-2025
4.5.1.3 Zioptan: Acquired from Merck
4.5.1.4 Zioptan: Sales Forecast 2015-2025
4.5.1.5 Cosopt/Cosopt PF: Acquired from Merck
4.5.1.6 Cosopt/Cosopt PF: US Sales Forecast 2015-2025
4.5.2 Akorn: Revenue Forecast 2015-2025
4.5.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2015-2025
4.5.3 Akorn: SWOT Analysis
5. Leading European Ophthalmic Drug Manufacturers 2015-2025
5.1 Bayer Overview
5.1.1 Eylea: non-US Sales Forecast 2015-2025
5.1.2 Bayer: Revenue Forecast 2015-2025
5.1.2.1 Bayer: Ophthalmic Drugs Market Share Forecast 2015-2025
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: Best-Selling Ophthalmic Drug in 2014
5.2.1.2 Lucentis: Non-US Sales Forecast 2015-2025
5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2015-2025
5.2.1.5 Vigamox: Competes with Alcon’s Moxeza
5.2.1.6 Vigamox: Sales Forecast 2015-2025
5.2.1.7 Azopt: Marketed in Major Markets
5.2.1.8 Azopt: Sales Forecast 2015-2025
5.2.1.9 Jetrea: Sales Revenues Fall Short
5.2.1.10 Jetrea: Non-US Sales Forecast 2015-2025
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.2.2.2 AKB 9778 (Aerpio Therapeutics)
5.2.3 Novartis: Revenue Forecast 2015-2025
5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2015-2025
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.1.1 Lucentis: US Sales Forecast 2015-2025
5.3.1.2 Avastin: Will It Remain Off-Label Use for Wet AMD?
5.3.1.3 Avastin: Sales Forecast 2015-2025
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.2.1 Lampalizumab (RG7417)
5.3.3 Roche: Revenue Forecast 2015-2025
5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2015-2025
5.3.4 Roche: SWOT Analysis
5.3.4.1 Lucentis Granted Fourth Approval in the US
6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2015-2025
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2015-2025
6.1.1.2 Hyalein: Santen’s Best Selling Drug in 2014
6.1.1.3 Hyalein: Sales Forecast 2015-2025
6.1.1.4 Cosopt: Non-US Sales Forecast 2015-2025
6.1.1.5 Tapros/Taflotan: Sales Forecast 2015-2025
6.1.1.6 Diquas: Sales Forecast 2015-2025
6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
6.1.1.8 Cravit: Sales Forecast 2015-2025
6.1.1.9 Trusopt: Non-US Sales Forecast 2015-2025
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2015-2025
6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2015-2025
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y 39983 (SNJ 1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2015-2025
6.2.3.1 Senju: Ophthalmic Drugs Market Share Forecast 2015-2025
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.1.1 Timoptic: US Sales Forecast 2015-2025
6.3.1.2 Bromday: New Formulation Released
6.3.1.3 Bromday: Sales Forecast 2015-2025
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.2.1 Vesneo (BOL 303259-X)
6.3.2.2 MIM-D3 (tyrosine kinase receptor antagonist, Valeant)
6.3.2.3 Brimonidine for Eye Whitening (Valeant)
6.3.3 Valeant: Revenue Forecast 2015-2025
6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2015-2025
6.3.4 Valeant: SWOT Analysis
6.3.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
7. Emerging Ophthalmic Drug Manufacturers in 2015
7.1 Pipeline and Other Companies, 2015
7.2 Abbott: Fenofibrate Approved in Australia for Diabetic Retinopathy
7.3 Acucela
7.4 Aerie Pharmaceuticals
7.5 Aerpio Therapeutics: Developing AKB 9778
7.6 Alimera Sciences
7.6.1 Iluvien Gained Recent FDA Approval
7.6.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.7 Altheos
7.8 Amakem
7.9 Ampio Pharmaceuticals
7.10 BioDiem
7.10.1 BDM-E: A High-Value Divestment?
7.11 Can-Fite BioPharma/OphthaliX
7.12 Chengdu Kanghong Pharmaceutical
7.13 Eleven Biotherapeutics
7.14 EyeGate Pharmaceuticals
7.15 Gene Signal
7.15.1 Aganirsen: Preventing Corneal Graft Rejection
7.16 GSK
7.16.1 Darapladib for Diabetic Macular Oedema
7.17 Icon Bioscience
7.18 Lpath
7.18.1 iSONEP: Antibodies Against Bioactive Lipids
7.19 MacuCLEAR
7.19.1 MC 1101: a Potential Therapy for Dry AMD
7.20 Neurotech
7.20.1 Renexus (NT 501) for Dry AMD
7.21 Omeros
7.22 Ophthotech
7.22.1 Will Roche Succeed in Acquiring Fovista?
7.22.2 Fovista: Significant Improvement on Lucentis in Phase 2 Trials
7.22.3 Zimura: Complement C5 Inhibitor
7.23 Otsuka Pharmaceutical
7.24 OXiGENE: Developing Zybrestat for Wet AMD
7.25 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.26 Shire
7.26.1 Lifitegrast (SHP606) for Dry Eye
7.26.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.27 ThromboGenics
7.27.1 Jetrea (ocriplasmin)
7.27.1.1 Jetrea: US Sales Forecast 2015-2025
7.27.2 TB 403: Anti-Placental Growth Factor
8. Qualitative Analysis of the Ophthalmic Drugs Market 2015-2025
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]
9. Research Interviews
9.1 Interview with Dan Myers, President and CEO, Alimera Sciences
9.1.1 Alimera Sciences’ Key Products
9.1.2 Expectations for the Launch of Iluvien in the US and EU
9.1.3 Alimera Sciences’ Plans for Growth
9.1.4 Alimera Sciences’ Ophthalmic Pipelines
9.1.5 Challenges in the Ophthalmic Drugs Market
9.1.6 Treatment Change in Retinal Disorders in the Next Decade
9.1.7 Successful Therapies in Ophthalmology in the Next Decade
9.1.8 Trends and Developments in the Ophthalmic Drugs Market
9.2 Interview with Dr. Leigh Hsu, Vice President, Corporate Development and Strategy, Lpath Inc.
9.2.1 Lpath’s Work in Ophthalmology
9.2.2 Progress Update on iSONEP in Clinical Development
9.2.3 Planned Phase 3 Trials in 2015?
9.2.4 Lpath’s Plans for Growth
9.2.5 Main Unmet Needs in Ophthalmology
9.2.6 Promising New Drug Targets in Development
9.2.7 Potential Treatments for Retinal Disorders in the Next Decade
9.2.8 Trends in Ophthalmology: Combination Therapy, Implants, Delivery Methods
9.3 Interview with a Spokesperson for Vanda Pharmaceuticals, Washington DC, US
9.3.1 Commercialising Hetlioz
9.3.2 Future Prospects for Vanda
10. Conclusions
10.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
10.2 The World Ophthalmic Drugs Market in 2014
10.2.1 Leading Ophthalmic Drugs Market Segments
10.2.2 Leading Ophthalmic Drugs
10.2.3 Leading Ophthalmic Drugs Companies
10.3 World Ophthalmic Drugs Market Forecast 2015-2025
10.4 The Future of the Ophthalmic Drugs Market?
10.4.1 Increasing Revenue Concentration among Specialist Companies
10.4.2 The Rise of Generics
10.4.3 Small Companies Can Have a Big Impact
10.4.4 What Will Succeed in the Ophthalmic Drugs Market?
11. Glossary
【レポート販売概要】
■ タイトル：世界の眼疾患治療薬分野における主要な製薬企業分析■ 英文：Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025
■ 発行日：2015年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN503041
■ 調査対象地域：グローバル
- モータ保護装置の世界市場：過負荷継電器、真空接触器、コンビネーションスタータ、回路遮断器The global motor protection market is projected to grow at a CAGR of 6.86% during the forecast period to reach a value of USD 5.09 Billion by 2020. The growth is attributed to growing focus on safety towards motors and robust growth in the HVAC market. The motor protection market, on the basis of device type, has been categorized into four segments: overload relays, vacuum contactors, and combinat …
- ノーメックス・ハニカムの世界市場予測（～2021）The global Nomex honeycomb market is estimated to grow from USD 237.1 Million in 2015 to USD 383.3 Million by 2021, at a compound annual growth rate (CAGR) of 8.51% between 2016 and 2021. The global Nomex honeycomb market has witnessed a strong growth in the past few years due to its high demand from the aerospace & defense application segment. Nomex honeycomb provides high-strength to weight rati …
- 世界の無線POS端末市場動向（2012-2016）TechNavio's analysts forecast the Global Wireless POS Terminal market to grow at a CAGR of 7.7 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing necessity to improve hospitality and reliability among customers. The Global Wireless POS Terminal market has also been witnessing the increasing organized logistics sector in emerging countries …
- 暗号化管理ソリューションの世界市場2019-2023About this market The increasing number of cyber threats is one of the key factors expected to trigger market growth in the forthcoming years. Cybersecurity is a growing concern intensifying due to digital innovations and rising volume of digital information. Interoperability among various sectors including the healthcare and BFSI sector for digitalized service developments are also increasing, in …
- チャーチ管理ソフトウェアの世界市場2019-2023About this market The increasing number of vendors offering low-cost, trial versions of church management software will propel the market growth in the forthcoming years. Vendors are offering trial versions for providing churches a chance to try and test the software and let them decide if they want to buy it or not. Some vendors are also providing a free trial version of the software with limited …
- 硫酸ナトリウムの世界市場予測Praduct 2014 World Market Outlook and Forecast is an absolutely essential resource for anyone looking for detailed information on the mentioned market. Using a wide range of primary and secondary sources, we combined, analyzed and presented all available data about sodium sulfate market in the all-in-one report issued in a logical and easily accessible format. In addition to the analytical part, t …
- イソシアネート（Isocyanate）の世界市場：ジフェニルメタンジイソシアネート（MDI）、トルエンジイソシアネート（TDI）、脂肪族イソシアネートAbout Isocyanates Isocyanates are highly reactive chemicals that are used to manufacture polyurethanes, which are used in various industrial and commercial sectors. The most common type of isocyanates used are Methylene Diphenyl Diisocyanate (MDI) and Toluene Diisocyanate (TDI).However, isocyanates are hazardous in nature and may cause irritation to skin, breathing problems, and may also cause whe …
- ポリフェノールの世界市場分析：製品別（ブドウの種、緑茶、アップル）、用途別（機能性食品、機能性飲料、栄養補助食品）、セグメント予測The global polyphenols market is expected to reach USD 1.33 billion by 2024, according to a new report by Grand View Research, Inc. Growing geriatric population base in the U.S., Western Europe, and Japan is expected to drive polyphenols demand over the forecast period. The growing demand for polyphenols from the niche nutraceutical and dietary supplement market to the wider food & beverage market …
- 世界の化粧板市場2015The Global Decorative Laminates Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Decorative Laminates industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Decorative Laminates market analysis is provided for the international markets including develop …
- パスタ及び麺（ヌードル）食品市場：アンドラ（～2017）Synopsis "Pasta and Noodles Market in Andorra: Databook to 2017" is the result of Canadean's extensive market research covering the Pasta and Noodles market in Andorra. The report presents detailed historic and forecast data on the Pasta and Noodles consumption trends in Andorra, offering consumption volume and value at market and category level. Bringing together Canadean's research, modeling, an …
- Freehold Royalties Ltd.：石油・ガスの開発・生産動向及びコスト分析– Q4, 2012Freehold Royalties Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2012 Summary Freehold Royalties Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential so …
- グローバルにおけるCRAMS（医薬品研究開発・製造受託サービス）市場（～2018）The industry research publication titled ‘Global CRAMS Market Outlook to 2018 – India and China Present Bright Prospects’ presents a comprehensive analysis of market size by value of CRAMS services in globally. The report entails the market share analysis and company profiles of major players in the CRAMS industry. The future analysis and segmentation by geographies, drugs and devices and therapeu …
- バイオバーデン試験の世界市場：装置（PCR、顕微鏡、微生物識別システム）、消耗品（キット、試薬）The bioburden testing market is expected to reach $565.6 million by 2019 from $354.4 million in 2014, at a CAGR of 9.8% from 2014 to 2019. This market is segmented on the basis of products, test types, applications, end users, and regions. On the basis of end users, the market is segmented into pharmaceutical and biotechnology companies, medical device manufacturers, contract manufacturing organiz …
- 複合材料の世界市場：インサイト、市場機会、市場シェア、市場予測Worldwide composites market has generated a revenue of approx. $69.50 Billion in 2015 and is projected to generate the revenue of more than $106 Billion in 2022 at a CAGR of approx. 7.11%. Increasing demand for lightweight materials in various industries and increasing demand of wind energy becomes the major driver which helps to increase the market of the composites globally. Due to its increasin …
- リン酸鉄リチウム（LFP）電池の世界市場2016-2020About Lithium Iron Phosphate Batteries Lithium iron phosphate batteries (LFP) are used in high-power applications, such as HEVs, EVs, and consumer electronics devices. They are rechargeable batteries that use iron phosphate as a cathode and carbon as an anode. Lithium iron phosphate batteries have good electrochemical performance and low resistance. The advantages of using these batteries include …
